This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Inhaled Glucocorticosteroid Administration in Asthma Patients

This study has been completed.
Information provided by:
Hamamatsu University Identifier:
First received: November 15, 2007
Last updated: March 13, 2009
Last verified: March 2009
Once-daily inhaled glucocorticosteroids treatment can sufficiently control airway inflammation in asthma patients.

Condition Intervention Phase
Asthma Drug: Budesonide,hydrofluoroalkane-beclomethasone dipropionate Drug: Budesonide,hydrofluoroalkane-beclomethasone Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Phase 4 Study of Once-Daily Inhaled Glucocorticosteroid Administration in Asthma Patients

Resource links provided by NLM:

Further study details as provided by Hamamatsu University:

Primary Outcome Measures:
  • once-daily administration of inhaled glucocorticosteroids can control airway inflammation [ Time Frame: two-year ]

Enrollment: 24
Study Start Date: November 2005
Study Completion Date: March 2007
Groups/Cohorts Assigned Interventions
receive once-daily administration of inhaled glucocorticosteroids at bedtime
Drug: Budesonide,hydrofluoroalkane-beclomethasone
once-daily administration at bedtime
receive twice-daily administration of inhaled glucocorticosteroids
Drug: Budesonide,hydrofluoroalkane-beclomethasone dipropionate
receive twice-daily administration


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
University Hospital

Inclusion Criteria:

  • Receive ICS for one year or more, with no change in dose within the previous 8 weeks

Exclusion Criteria:

  • Two or more courses of oral corticosteroid in the previous 12 months
  • Admission to hospital due to asthma in the previous 6 months
  • Admission to the intensive care unit due to asthma at any time in the past
  • Current cigarette smoker.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00559689

Hamamatsu University School of Medicine
Hamamatsu, Japan, 431-3192
Sponsors and Collaborators
Hamamatsu University
Study Chair: Kingo Chida, MD,PhD
  More Information Identifier: NCT00559689     History of Changes
Other Study ID Numbers: Hamamatsu-17-43
Study First Received: November 15, 2007
Last Updated: March 13, 2009

Keywords provided by Hamamatsu University:
asthma patients

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 18, 2017